In this video, Susan F. Slovin, MD, PhD, discusses considerations that physicians should know when they are beginning to implement immunotherapy in their practice, which are ideas associated with a presentation that she gave at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Slovin is a medical oncologist at the Memorial Sloan Kettering Cancer Center in New York City, New York.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.